NOVA
#68ScienceDecentralized drug discovery screening 1.75B+ synthesizable compounds against therapeutic protein targets 24/7.
Price
24h
7d Change
Market Cap
Emission
Miners
Validators
Competitor Mapping
NOVA
Decentralized
Market Cap
$27.92M
TAM
$5.00B
Model
Token-incentivized
Team
Decentralized miners
Schrodinger Inc.
SDGR
Market Cap
$900.00M
TAM
$5.00B
Model
Revenue-driven
Team
Enterprise
Crowdsources molecular screening via miners while Schrodinger charges enterprise licenses for physics-based drug discovery. 20+ year pharma partnership gap.
Implied Valuation
If NOVA captures a share of Schrodinger Inc.'s $5.00B TAM
Bear - 0.1% TAM
$5.00M
implied valuation
vs $27.92M current
Base - 1% TAM
$50.00M
implied valuation
vs $27.92M current
Bull - 5% TAM
$250.00M
implied valuation
vs $27.92M current
Scenarios illustrate potential scale relative to the traditional market. Actual outcomes depend on adoption, tokenomics, and competitive dynamics.
Thesis
Drug discovery is $65B+ dominated by slow, expensive approaches. Always-on screening of 1.75B compounds creates throughput no single lab matches. DeSci narrative is powerful for capital formation.
Team
Founded by Micaela Bazo (CEO). Dr. Pedro Penna serves as science lead (Director at NAIAD Drug Design, vision to merge decentralized AI with drug development). Team based in Austin, TX. Composed of experts in AI, ML, and drug discovery. Team is doxxed.
- Micaela Bazo - CEO & Founder - Crypto-native biotech background
- Dr. Pedro Penna - Science Lead - Director at NAIAD Drug Design, PhD in computational chemistry/drug discovery
Funding
No confirmed VC funding rounds disclosed. Pre-revenue biotech model with multiple future revenue paths (pharma partnerships, IP licensing, platform fees).
Traction
4.8M molecules screened across 7,000 targets. DiaGen AI joint venture LOI signed to develop hit-picking tool for automating drug discovery. Approaching wet lab validation. Multiple revenue paths including pharma collaborations. METANOVA trademark filed at USPTO.
Recent News
- 2026 - DiaGen AI Inc. announced joint venture LOI with Metanova Labs for hit-picking tool
- 2026 - Subnet Magazine interview with Micaela Bazo and Dr. Pedro Penna
- 2026 - Wet lab testing approaching for initial compounds
- 2025 - Launched NOVA on Bittensor SN68
Risk
In-silico screening is the easy part; wet-lab validation and clinical trials remain bottlenecks decentralized networks can't solve.